Literature DB >> 8259281

Progressive Schnyder's corneal dystrophy.

H J Ingraham1, H D Perry, E D Donnenfeld, D D Donaldson.   

Abstract

BACKGROUND: Schnyder's crystalline dystrophy is a central anterior bilateral corneal dystrophy characterized by the deposition of crystals composed of cholesterol and other lipids. This condition classically is described as nonprogressive after childhood, but a series of recent studies following patients over time has challenged this teaching. PATIENTS: The authors present a family pedigree including a patient first reported in 1954 and followed for 25 years with dramatic progression of the corneal condition in a dense, discoid pattern of crystals. Best-corrected visual acuity decreased from 20/30 to 20/80 in both eyes. This patient now has three children, all with typical corneal involvement.
RESULTS: Ocular pathologic examination performed on corneal biopsies submitted for light and electron microscopy demonstrated cholesterol deposition consistent with a diagnosis of Schnyder's.
CONCLUSION: Schnyder's corneal dystrophy may progress significantly over time. The characterization of this condition as stationary may need to be reconsidered.

Entities:  

Mesh:

Year:  1993        PMID: 8259281     DOI: 10.1016/s0161-6420(93)31391-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  3 in total

1.  [Schnyder's crystalline corneal dystrophy. Further narrowing of the linkage interval at chromosome 1p34.1-p36?].

Authors:  P Riebeling; S Polz; F Tost; J S Weiss; H Kuivaniemi; M Hoeltzenbein
Journal:  Ophthalmologe       Date:  2003-11       Impact factor: 1.059

2.  Visual morbidity in thirty-four families with Schnyder crystalline corneal dystrophy (an American Ophthalmological Society thesis).

Authors:  Jayne S Weiss
Journal:  Trans Am Ophthalmol Soc       Date:  2007

3.  Functional study of SCCD pathogenic gene UBIAD1 (Review).

Authors:  Jumin Xie; Lingxing Li
Journal:  Mol Med Rep       Date:  2021-08-09       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.